News & analysis on the clinical development and manufacture of large molecule drugs
By Ben Hargreaves
- Last updated on
Angus Grant has been installed in the role of chief business executive with BeiGene, where he will report directly to John Oyler, CEO of the biotech.
Grant will be tasked with overseeing business development, alliance management, and driving BeiGene’s global growth strategy.
The Chinese biotech has been growing rapidly in the decade since its inception, building up a team including 1,200 people in clinical development and 1,300 in commercial roles in China.
As a result, the biotech was recently backed by investors, particularly Amgen, in raising $2bn (€1.7bn), which it plans to utilize to develop its pipeline of therapies.
Grant enters the role having most recently worked as CEO of the Dementia Discovery Fund – a venture capital fund focused on treatment for dementia and neurogenerative disease.
Prior to that, he had developed a comprehensive amount of experience working in the pharma industry, including 12 years working in business development at Celgene, as well as roles at Novartis, Merck KGaA, and the US Food and Drug Administration.